BIO-Europe Spring® 2017: Shanghai Henilus Biotech has blockbuster biologics in biosimilar crosshairs

April 10, 2017
With a number of monoclonal blockbusters—notably Roche’s Rituxan and Herceptin—approaching patent expiry in key markets, it is not surprising that a queue is forming to create biosimilar competitors. Dr. Cheni Kwok, a business development and strategy consultant, caught up with Scrip’s Mike Ward to outline how Shanghai Henilus Biotech is positioning itself to provide affordable healthcare globally. Shanghai Henilus Biotech is an eight-year-old joint venture formed by Shanghai Fosun Pharmaceutical and Henilus Biopharmaceuticals, established by San Francisco Bay area biotech veterans, that has built research, clinical development and manufacturing capabilities. On the cusp of commercialization of lead programs—expecting to file the first Rituxan biosimilar in China next year, while completing Phase III trials in Europe and China of a Herceptin biosimilar—the company is looking beyond China to establish partnerships.
Previous Video
BIO-Europe Spring® 2017: Prexton CEO on future for novel Parkinson's therapy
BIO-Europe Spring® 2017: Prexton CEO on future for novel Parkinson's therapy

As Prexton Therapeutics prepares to move its lead compound foliglurax into Phase II trials as a symptomatic...

Next Video
BIO-Europe Spring® 2017: Sinergium provides gateway to Latin American vaccine and biologics markets
BIO-Europe Spring® 2017: Sinergium provides gateway to Latin American vaccine and biologics markets

With the Latin American vaccines market forecast to more than quadruple in size from just over USD 150 mill...